KONEXChemicals331660

Korea Miracle People Company

₩3,880 0.00%2026-11-18 close
Market Cap
₩21.3B
Turnover
₩0
Volume
0 shares
Shares out.
5.5M
PER
—
PBR
—
EPS
—
Dividend Yield
0.00%

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Detergent Core, Cosmetics Ambition

Korea Miracle People Company is layering capsule-detergent automation, biocide certification and a cosmetics push onto a profitable eco-detergent core, while its thin liquidity and slim equity base remain part of the picture.

  1. 1

    In 2025, revenue rose 10.1% year on year, with operating profit of KRW 1.39 billion and net income of KRW 2.72 billion.

  2. 2

    Gross profit grew 42.1%, but SG&A expenses rose 66.7% and operating profit fell 29.1%. Top-line growth and profitability moved in opposite directions.

  3. 3

    Independent research house Aris estimates 2026 consolidated revenue of KRW 40.0 billion and operating profit of KRW 4.0 billion. This is an outside estimate, not reported results.

  4. 4

    The company has appointed IBK Investment & Securities as designated adviser to pursue a KOSDAQ transfer, and has changed its registered main industry to cosmetics.

  5. 5

    The close on October 27, 2026 was KRW 3,850, for a market capitalization of KRW 21.2 billion. Traded value that day was zero, which illustrates the thin liquidity typical of KONEX.

02

Business structure

Korea Miracle People Company is an eco-friendly household chemicals maker headquartered in Pocheon, Gyeonggi Province. It began as a sole proprietorship in 2004 and was incorporated in May 2014. It listed on the KONEX market on October 28, 2019.

Its lineup covers kitchen and laundry detergents and cleaners, and its differentiation rests on natural-extract concentration technology such as orange oil and on silver nanoparticle synthesis. Its main brands are Silvernano Step and Top Step.

By 2023 revenue, products made up 99.27% of sales, with domestic sales at 94.18% and exports at 5.82%. Production is handled by two plants and an R&D center in Pocheon.

The company is building up cosmetics, citing a cumulative 300 million sheet masks produced and generation-targeted brands, and has changed its registered main industry to cosmetics.

The largest shareholder is GP Club (55.78% as of December 5, 2024), and the two companies cooperate on cosmetics ODM/OEM such as sheet masks. Reportedly, sales to the affiliate JOR R&D reached KRW 10.7 billion in 2024, about 36% of total revenue, so related-party dependence is an issue.

Although classified as chemicals, the business differs in nature from large petrochemical and materials names such as LG Chem and Lotte Chemical, which limits direct comparison.

03

Recent trends

In its 2025 annual report, the company posted revenue of KRW 30,380,616 thousand, up 10.1% from KRW 27,597,168 thousand. Gross profit rose 42.1% to KRW 10.8 billion. However, SG&A expenses climbed 66.7%, and operating profit fell 29.1% to KRW 1,393,704 thousand.

Net income rose 178.2% to KRW 2,725,418 thousand, helped considerably by income tax recorded as a KRW 1.46 billion gain. Non-operating items therefore need to be separated when judging earnings quality. Operating cash flow was an inflow of KRW 2.29 billion, compared with an outflow of KRW 1.24 billion the year before.

Total equity at the end of 2025 was KRW 2,267,119 thousand, moving out of the prior-year capital deficit of KRW 1,025,799 thousand.

Since the company had booked an operating loss of KRW 3.0 billion in 2023, the return to profit over the last two years is meaningful, but results for the first half and third quarter of 2026 could not be confirmed.

The share price was KRW 16,000 on March 31, 2026, and the trading halt for the stock split was lifted on May 6. On a split-adjusted basis, the September 14, 2026 close was shown as KRW 3,910, with a 52-week range of KRW 870 to KRW 4,740. The October 27 close was KRW 3,850, with zero traded value.

04

Outlook

There are four main growth drivers. The first is capsule detergent. Top Step capsule output rose from 114,531 units in 2021 to 2,173,853 in 2025, and OEM/ODM customers increased from 8 to 49. To counter low-priced Chinese products, the company is building unmanned automated production lines. The second is biocides.

Under a Ministry of Environment notice, products that have not completed approval face sales restrictions from June 2026. The company said it was finalizing domestic approval for its mold-removal gel, and that overseas certification takes about a year, with completion targeted within 2026 or by the first half of 2027.

The approval outcome, however, could not be confirmed. The third is cosmetics, and the fourth is the KOSDAQ transfer. Citing higher capsule output, an oligopoly effect from tighter biocide rules and sheet-mask exports, Aris estimates 2027 revenue of KRW 68.0 billion and operating profit of KRW 9.6 billion.

Meeting that estimate would require a sharp improvement from 2025 operating profit of KRW 1.39 billion, and room for margin gains depends on automation-driven cost savings and SG&A control.

05

Bull factors

Capsule detergent growth and automation

Capsule output grew roughly 20-fold in four years, and OEM/ODM customers rose to 49. Running its own brand alongside contract manufacturing is widening the customer base. Unmanned automated lines could ease labor cost pressure. A better cost structure would leave room for operating margin to recover from the dip caused by higher SG&A.

Biocide rules and overseas certification

Biocide management is moving to prior approval, restricting sales of unapproved products. That creates an entry barrier for firms that secure approval. Future Market Report projects the global mold remover market at about USD 23.9 billion by 2032, growing at more than 7.2% a year. The company describes the product as high-margin, but that is management's own claim.

Balance sheet repair and expansion

Total equity turned positive at the end of 2025, ending the capital deficit. Operating cash flow also turned to an inflow in 2025. The KOSDAQ transfer effort and the cosmetics-led restructuring are moving in parallel. On May 19, 2026, the company received the Best Marketing Award at the KONEX Awards.

06

Bear factors

SG&A surge and earnings quality

SG&A expenses rose 66.7% in 2025 and operating profit fell 29.1%. If cosmetics expansion and marketing spending continue, profitability pressure could persist. Net income was lifted by a KRW 1.46 billion income tax gain. Recurring earnings power is closer to the KRW 1.39 billion operating profit.

Related-party reliance and governance

A news report criticized the company for deteriorating results after the GP Club acquisition, with a 2023 operating loss of KRW 3.0 billion. Affiliate sales reportedly reached about 36% of total revenue in 2024.

Where a controlling shareholder holds this much influence, transaction terms and sales sustainability need monitoring. On the board, the company disclosed on March 31, 2026 that two outside directors were newly appointed and one resigned.

Thin equity and low liquidity

Total equity at the end of 2025 was a small KRW 2.27 billion, and an accumulated deficit of KRW 0.57 billion remains. With a heavy debt load, any wobble in operating profit could affect financial stability. Traded value on October 27, 2026 was zero. KONEX shares trade infrequently, so quoted and actually executable prices can differ.

07

Risk factors

Regulatory and certification

Products without domestic biocide approval face sales restrictions from June 2026. Overseas certification is reported to take about a year. US, EU and UK certifications could be delayed or end differently. The business's contribution can only be gauged once approvals are confirmed.

Competition and cost

The company itself names price competition from low-cost Chinese products as a challenge. Raw material prices such as orange concentrate and surfactants have been cited as a factor affecting profitability. The mask pack and cosmetics markets are also highly competitive. The cost savings from automation have not yet appeared in reported results.

Market and listing

The KOSDAQ transfer was planned for the second half of 2026, but it requires an exchange review and no outcome has been confirmed. Outside estimates are not company results and may differ materially. Small KONEX stocks can move sharply on few trades. The wide split-adjusted 52-week range of KRW 870 to KRW 4,740 illustrates this.

08

Overall view

Korea Miracle People Company posted profits in both 2024 and 2025 from its eco-detergent core and moved out of a capital deficit at the end of 2025. Capsule-detergent automation, biocide rule compliance and cosmetics expansion form the growth case.

In 2025, however, higher SG&A reduced operating profit, and net income was influenced by an income tax gain. Reliance on affiliate sales, a small equity base and thin liquidity, shown by zero traded value, also need to be weighed.

Aris's 2026 and 2027 figures are outside estimates, to be tested against actual first-half and third-quarter results, biocide approvals and the KOSDAQ transfer outcome. This material is for information only, and the judgment is left to the reader.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 13 more articles and sources
  1. kind.krx.co.kr
  2. kind.krx.co.kr
  3. mt.co.kr
  4. newspim.com
  5. newsis.com
  6. newspim.com
  7. edaily.co.kr
  8. ekn.kr
  9. m.news.nate.com
  10. news.nate.com
  11. m.news.nate.com
  12. m.news.nate.com
  13. stockanalysis.com

Report written 2026-10-27 · Data as of 2026-10-26

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis